Full Breakdown
GeneDx Showcases Innovations in Genetic Diagnosis at NSGC 2025
11/7/2025, 11:45:55 AM
Advancements in Gene-Disease Discovery
GeneDx, a leader in genomic insights and rare disease diagnosis, is set to present significant research findings at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting. The company will highlight its GeneDx Infinity™ platform, which boasts the largest rare disease dataset, and aims to enhance diagnostic accuracy and access to precision medicine. Britt Johnson, PhD, FACMG, Senior Vice President of Medical Affairs at GeneDx, emphasized the company's commitment to accelerating gene-disease insights and improving patient outcomes through innovative genomic testing.
Key Presentations and Research Findings
During the NSGC meeting, GeneDx will conduct four key sessions focused on various aspects of genetic diagnosis:
1. Scaling Clinical Interpretation: Maria Guillen Sacoto, MD, FACMG, will discuss a framework for validating gene-disease associations, which has curated over 9,000 associations to support accurate diagnoses for families affected by rare diseases.
2. Long-Read Sequencing: Flavia Facio, MS, CGC, will present data on the performance of high-fidelity long-read sequencing in clinical samples, demonstrating its ability to identify challenging variants and improve diagnostic speed and accuracy.
3. Impact of Genomic Data: A session titled "The Ripple Effect of Genomics Data" will showcase how large-scale genomic data can accelerate variant interpretation and support drug development, featuring contributions from leaders in patient advocacy and health economics.
4. Reimbursement and Access: Sarah Soto, MC, CGC, will address the evolving reimbursement landscape for genetic testing, providing insights on how genetic counselors can advocate for equitable access to these essential services.
Why It Matters
GeneDx's advancements in genomic testing are pivotal for enhancing the standard of care in rare disease diagnosis. The integration of real-world data and innovative technologies positions GeneDx as a key player in the shift towards proactive healthcare, moving beyond traditional sick care models. The company's efforts to empower genetic counselors with tools and insights are expected to transform patient care and improve health outcomes for families dealing with rare diseases.
Criticism & Opposition
While GeneDx's initiatives are largely viewed positively, some critics express concerns regarding the accessibility of genomic testing and the complexities of navigating insurance reimbursement. The evolving landscape of genetic testing reimbursement may pose challenges for genetic counselors and patients alike, necessitating ongoing dialogue and advocacy.
Official Statements & Responses
GeneDx's leadership has reiterated its commitment to advancing precision medicine through innovation and real-world evidence. The company aims to shape equitable access to genetic testing and improve diagnostic accuracy for rare diseases, emphasizing the importance of collaboration with genetic counselors and healthcare providers.
Verbatim Quotes
- “GeneDx is at the forefront of genomic discovery, accelerating gene-disease insights, advancing long-read sequencing, and improving access so more families can reach answers sooner,” — Britt Johnson, PhD, FACMG, SVP of Medical Affairs, GeneDx
- “This breakthrough not only accelerates crop improvement but also demonstrates how our faculty and students are addressing some of the most pressing challenges in global food security and sustainable production.” — Clint Krehbiel, Dean, Davis College of Agricultural Sciences and Natural Resources, Texas Tech University
GeneDx's participation in the NSGC 2025 Annual Meeting underscores its role in the future of genetic diagnosis and precision medicine, aiming to provide timely and accurate solutions for families affected by rare diseases.
